Division of Hematology/Oncology

74(top 1%)

papers

2.6K(top 1%)

citations

29(top 1%)

h-index

51(top 1%)

g-index

all documents

2.7K

doc citations

926

citing journals

Top Articles

#	Title	Journal	Year	Citations
1	The Kinase Inhibitor Sorafenib Induces Cell Death through a Process Involving Induction of Endoplasmic Reticulum Stress	Molecular and Cellular Biology	2007	209
2	Health related quality of life in sickle cell patients: the PiSCES project	Health and Quality of Life Outcomes	2005	207
3	A randomized trial comparing prednisone with antithymocyte globulin/prednisone as an initial systemic therapy for moderately severe acute graft-versus-host disease	Biology of Blood and Marrow Transplantation	2000	133
4	Comparisons of High Versus Low Emergency Department Utilizers in Sickle Cell Disease	Annals of Emergency Medicine	2009	115
5	Development of Platelet Contractile Force as a Research and Clinical Measure of Platelet Function	Cell Biochemistry and Biophysics	2003	107
6	Cyclin-dependent kinase inhibitors	Current Opinion in Pharmacology	2003	99
7	Combined treatment with the checkpoint abrogator UCN-01 and MEK1/2 inhibitors potently induces apoptosis in drug-sensitive and -resistant myeloma cells through an IL-6–independent mechanism	Blood	2002	96
8	A Bim-targeting strategy overcomes adaptive bortezomib resistance in myeloma through a novel link between autophagy and apoptosis	Blood	2014	82
9	The Bruton tyrosine kinase (BTK) inhibitor PCI‐32765 synergistically increases proteasome inhibitor activity in diffuse large‐B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib	British Journal of Haematology	2013	81
10	Cotreatment with Suberanoylanilide Hydroxamic Acid and 17-Allylamino 17-demethoxygeldanamycin Synergistically Induces Apoptosis in Bcr-Abl+Cells Sensitive and Resistant to STI571 (Imatinib Mesylate) in Association with Down-Regulation of Bcr-Abl, Abrogation of Signal Transducer and Activator of Transcription 5 Activity, and Bax Conformational Change	Molecular Pharmacology	2005	80
11	Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia models	Haematologica	2020	78
12	Identification of novel human tumor cell-specific CaMK-II variants	Biochimica Et Biophysica Acta - Molecular Cell Research	1997	62
13	The NF (Nuclear factor)‐κB inhibitor parthenolide interacts with histone deacetylase inhibitors to induce MKK7/JNK1‐dependent apoptosis in human acute myeloid leukaemia cells	British Journal of Haematology	2010	62
14	Carfilzomib Interacts Synergistically with Histone Deacetylase Inhibitors in Mantle Cell Lymphoma Cells In Vitro and In Vivo	Molecular Cancer Therapeutics	2011	60
15	Gender Differences in Pain and Healthcare Utilization for Adult Sickle Cell Patients: The PiSCES Project	Journal of Women's Health	2006	59
16	Bortezomib interacts synergistically with belinostat in human acute myeloid leukaemia and acute lymphoblastic leukaemia cells in association with perturbations in NF‐κB and Bim	British Journal of Haematology	2011	56
17	The use of cyclin-dependent kinase inhibitors alone or in combination with established cytotoxic drugs in cancer chemotherapy	Drug Resistance Updates	2003	54
18	Continuous Lidocaine Infusion for the Relief of Refractory Malignant Pain in a Terminally Ill Pediatric Cancer Patient	Journal of Pediatric Hematology/Oncology	2002	52
19	CDK Inhibitors Upregulate BH3-Only Proteins to Sensitize Human Myeloma Cells to BH3 Mimetic Therapies	Cancer Research	2012	51
20	The Novel Chk1 Inhibitor MK-8776 Sensitizes Human Leukemia Cells to HDAC Inhibitors by Targeting the Intra-S Checkpoint and DNA Replication and Repair	Molecular Cancer Therapeutics	2013	51
21	BCL2L11/Bim as a dual-agent regulating autophagy and apoptosis in drug resistance	Autophagy	2015	45
22	Cytokinetically quiescent (G0/G1) human multiple myeloma cells are susceptible to simultaneous inhibition of Chk1 and MEK1/2	Blood	2011	42
23	A review of tumour lysis syndrome with targeted therapies and the role of rasburicase	Journal of Clinical Pharmacy and Therapeutics	2011	39
24	In Vitro and In Vivo Interactions between the HDAC6 Inhibitor Ricolinostat (ACY1215) and the Irreversible Proteasome Inhibitor Carfilzomib in Non-Hodgkin Lymphoma Cells	Molecular Cancer Therapeutics	2014	37
25	Neurotensin promotes the progression of malignant glioma through NTSR1 and impacts the prognosis of glioma patients	Molecular Cancer	2015	33
26	Marstacimab, a tissue factor pathway inhibitor neutralizing antibody, improves coagulation parameters of ex vivo dosed haemophilic blood and plasmas	Haemophilia	2019	32
27	BMI, irAE, and gene expression signatures associate with resistance to immune-checkpoint inhibition and outcomes in renal cell carcinoma	Journal of Translational Medicine	2019	32
28	Tell It Like It Is	Journal of Clinical Oncology	2000	31
29	An Intact NF-kappaB Pathway is Required for Histone Deacetylase Inhibitor Induced G1 Arrest and Maturation in U937 Human Myeloid Leukemia Cells	Cell Cycle	2003	31
30	Disruption of Src function potentiates Chk1-inhibitor–induced apoptosis in human multiple myeloma cells in vitro and in vivo	Blood	2011	29
31	Obatoclax Interacts Synergistically with the Irreversible Proteasome Inhibitor Carfilzomib in GC- and ABC-DLBCL Cells In Vitro and In Vivo	Molecular Cancer Therapeutics	2012	29
32	Fatal Loeffler's endocarditis due to hypereosinophilic syndrome	American Journal of Hematology	2007	28
33	Phase I trial and correlative laboratory studies of bryostatin 1 (NSC 339555) and high-dose 1-B-D-arabinofuranosylcytosine in patients with refractory acute leukemia	Clinical Cancer Research	2002	28
34	Circumvention of Mcl-1-Dependent Drug Resistance by Simultaneous Chk1 and MEK1/2 Inhibition in Human Multiple Myeloma Cells	PLoS ONE	2014	27
35	Bryostatin 1 and UCN-01 Potentiate 1-β-d-Arabinofuranosylcytosine-Induced Apoptosis in Human Myeloid Leukemia Cells through Disparate Mechanisms	Molecular Pharmacology	2003	25
36	Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) Promotes Mitochondrial Dysfunction and Apoptosis Induced by 7-Hydroxystaurosporine and Mitogen-Activated Protein Kinase Kinase Inhibitors in Human Leukemia Cells That Ectopically Express Bcl-2 and Bcl-xL	Molecular Pharmacology	2003	25
37	Persistent Anemia After Implantation of the Total Artificial Heart	Journal of Cardiac Failure	2012	25
38	Evidence-based follow-up of lung cancer patients	Seminars in Oncology	2003	24
39	PLK1 Inhibitors Synergistically Potentiate HDAC Inhibitor Lethality in Imatinib Mesylate–Sensitive or –Resistant BCR/ABL+ Leukemia Cells In Vitro and In Vivo	Clinical Cancer Research	2013	24
40	Rationale and Design of the Randomized Evaluation of Default Access to Palliative Services (REDAPS) Trial	Annals of the American Thoracic Society	2016	23
41	Flavopiridol enhances ABT-199 sensitivity in unfavourable-risk multiple myeloma cells in vitro and in vivo	British Journal of Cancer	2018	23
42	Coadministration of UCN-01 with MEK1/2 Inhibitors Potently Induces Apoptosis in	Cancer Biology and Therapy	2002	22
43	Explaining Marginal Benefits to Patients, When “Marginal” Means Additional but Not Necessarily Small	Clinical Cancer Research	2010	22
44	Positive transcription elongation factor b (P-TEFb) is a therapeutic target in human multiple myeloma	Oncotarget	2017	21
45	Imatinib mesylate (STI571) for myeloid malignancies other than CML	Leukemia Research	2004	20
46	Checkpoint Inhibitors for Non-Small Cell Lung Cancer Among Older Adults	Current Oncology Reports	2017	20
47	An intact NF-kappaB pathway is required for histone deacetylase inhibitor-induced G1 arrest and maturation in U937 human myeloid leukemia cells	Cell Cycle	2003	20
48	The IAP antagonist birinapant potentiates bortezomib anti-myeloma activity in vitro and in vivo	Journal of Hematology and Oncology	2019	19
49	Targeting CRL4 suppresses chemoresistant ovarian cancer growth by inducing mitophagy	Signal Transduction and Targeted Therapy	2022	17
50	Synergistic interactions between PLK1 and HDAC inhibitors in non-Hodgkin's lymphoma cells occur in vitro and in vivo and proceed through multiple mechanisms	Oncotarget	2017	16

Profile

Scientometrics

Citing Bodies

Division of Hematology/Oncology

Top Articles